返回单股研究

财报研究

LLY Q1 2026

Lilly reported first-quarter 2026 results, raised full-year guidance and highlighted Mounjaro, Zepbound, orforglipron and broader pipeline progress.

实际结果

Revenue
US$19.799 billion
Up 56% year over year
Reported diluted EPS
US$8.26
Up 170% year over year
Revenue volume effect
+65%
Year-over-year contribution, partly offset by a 13% lower realized-price effect

管理层指引

  • Lilly raised 2026 revenue guidance to US$82-US$85 billion and non-GAAP EPS guidance to US$35.50-US$37.00.

市场反应

+13.17%

2026-04-29 $851.21 → 2026-05-01 $963.33

口径：公告日前一交易日收盘至公告日后首个完整交易日收盘。

查看历史行情来源

官方来源

Lilly Reports First-Quarter 2026 Financial ResultsEli Lilly and Company · earnings已核验

抓取时间: 2026/7/11 上午12:00:00 [UTC]

发布时间: 2026/4/30 上午12:00:00

查看原始来源
Eli Lilly Investor RelationsEli Lilly and Company · company已核验

抓取时间: 2026/7/11 上午12:00:00 [UTC]

查看原始来源
Form 10-Q for the Quarter Ended March 31, 2026Eli Lilly and Company · filing已核验

抓取时间: 2026/7/11 上午12:00:00 [UTC]

发布时间: 2026/4/30 上午12:00:00

查看原始来源
LLY editorial research profileAlphaVue Research · editorial已核验

抓取时间: 2026/7/11 上午12:00:00 [UTC]